Craig Esq - Cingulate Gen VP
| CING Stock | USD 4.36 0.16 3.81% |
Insider
Craig Esq is Gen VP of Cingulate
| Age | 51 |
| Address | 1901 West 47th Place, Kansas City, KS, United States, 66205 |
| Phone | 913 942 2300 |
| Web | https://www.cingulate.com |
Cingulate Management Efficiency
The company has return on total asset (ROA) of (1.0433) % which means that it has lost $1.0433 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (2.7382) %, meaning that it created substantial loss on money invested by shareholders. Cingulate's management efficiency ratios could be used to measure how well Cingulate manages its routine affairs as well as how well it operates its assets and liabilities. At this time, Cingulate's Return On Capital Employed is most likely to slightly grow in the upcoming years. The Cingulate's current Return On Equity is estimated to increase to 3.60, while Return On Tangible Assets are forecasted to increase to (6.40). At this time, Cingulate's Non Currrent Assets Other are most likely to decrease significantly in the upcoming years. The Cingulate's current Debt To Assets is estimated to increase to 0.90, while Total Assets are projected to decrease to roughly 3.3 M.Similar Executives
| Showing other executives | INSIDER Age | ||
| Scott Anderson | Anebulo Pharmaceuticals | N/A | |
| Benjamin Dake | Aerovate Therapeutics | 48 | |
| Josh Eizen | AN2 Therapeutics | N/A | |
| George Eldridge | Aerovate Therapeutics | 61 | |
| Michael Alley | AN2 Therapeutics | N/A | |
| Surendra Singh | Inhibikase Therapeutics | N/A | |
| Eric Easom | AN2 Therapeutics | 56 | |
| David Mack | Pmv Pharmaceuticals | 62 | |
| Deborah Knobelman | Senti Biosciences | 50 | |
| MD FACP | AN2 Therapeutics | 76 | |
| Eric Devroe | Acrivon Therapeutics, Common | 45 | |
| Susan Kahlert | Senti Biosciences | N/A | |
| BSc FRCPC | Inhibikase Therapeutics | N/A | |
| MBA MD | Monopar Therapeutics | 38 | |
| Timothy Pigot | Aerovate Therapeutics | 53 | |
| Joseph Hazelton | Dyadic International | 48 | |
| LLM JD | Rezolute | 63 | |
| Donna Dea | Aerovate Therapeutics | N/A | |
| Jc MD | Adagene | 59 | |
| Robyn Sweinhart | Rezolute | N/A | |
| Winston MBA | Pmv Pharmaceuticals | 48 | |
Management Performance
| Return On Equity | -2.74 | ||||
| Return On Asset | -1.04 |
Cingulate Leadership Team
Elected by the shareholders, the Cingulate's board of directors comprises two types of representatives: Cingulate inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Cingulate. The board's role is to monitor Cingulate's management team and ensure that shareholders' interests are well served. Cingulate's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Cingulate's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Craig Esq, Gen VP | ||
| Dr MBA, Executive COO | ||
| Raul MD, Executive Officer | ||
| Thomas Dalton, Head Relations | ||
| Jennifer CPA, Senior CFO | ||
| Shane PharmD, CEO Board | ||
| PharmD PharmD, Principal CEO | ||
| Jennifer Callahan, Corporate Controller | ||
| Matthew MD, Executive Officer |
Cingulate Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Cingulate a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -2.74 | ||||
| Return On Asset | -1.04 | ||||
| Current Valuation | 3.69 M | ||||
| Shares Outstanding | 3.21 M | ||||
| Shares Owned By Insiders | 3.30 % | ||||
| Shares Owned By Institutions | 1.55 % | ||||
| Number Of Shares Shorted | 77.15 K | ||||
| Price To Book | 1.12 X | ||||
| Gross Profit | (9 M) | ||||
| EBITDA | (22.95 M) |
Currently Active Assets on Macroaxis
When determining whether Cingulate is a strong investment it is important to analyze Cingulate's competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact Cingulate's future performance. For an informed investment choice regarding Cingulate Stock, refer to the following important reports:Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Cingulate. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in board of governors. For more detail on how to invest in Cingulate Stock please use our How to Invest in Cingulate guide.You can also try the Pair Correlation module to compare performance and examine fundamental relationship between any two equity instruments.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Cingulate. If investors know Cingulate will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Cingulate listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (43.22) | Return On Assets (1.04) | Return On Equity (2.74) |
The market value of Cingulate is measured differently than its book value, which is the value of Cingulate that is recorded on the company's balance sheet. Investors also form their own opinion of Cingulate's value that differs from its market value or its book value, called intrinsic value, which is Cingulate's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Cingulate's market value can be influenced by many factors that don't directly affect Cingulate's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Cingulate's value and its price as these two are different measures arrived at by different means. Investors typically determine if Cingulate is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Cingulate's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.